FDA Accepts ID Biomedical’s Fluviral For Accelerated Approval Pathway
This article was originally published in The Pink Sheet Daily
Executive Summary
Accelerated approval could allow the company to market the influenza vaccine in the U.S. in time for the 2006-2007 flu season, the company says. ID Biomedical previously discussed the possibility of launching in 2005.
You may also be interested in...
GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
GlaxoSmithKline plans to acquire ID Biomedical for $1.4 bil., a deal that could provide GSK with a second flu vaccine in the U.S. for the 2006/2007 flu season.
GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
GlaxoSmithKline plans to acquire ID Biomedical for $1.4 bil., a deal that could provide GSK with a second flu vaccine in the U.S. for the 2006/2007 flu season.
ID Biomedical To Initiate Fluviral Trial For U.S. Approval By End Of January
ID Biomedical will begin enrolling subjects in a clinical trial evaluating its influenza vaccine Fluviral for U.S. approval before the end of January